ArticleAnnals of medicine and surgery (2012)2025
Xeroderma pigmentosum associated with recurrent squamous and basal cell carcinoma: a case report from Nepal.
Article in Annals of medicine and surgery (2012), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Xeroderma pigmentosum (XP) significantly increases the risk of skin malignancies due to impaired DNA repair mechanisms. The estimated incidence is 1 in 250 000 in the USA. Patients with XP are more likely to develop cutaneous neoplasms, primarily melanoma, squamous cell carcinoma (SCC), and basal cell carcinoma (BCC), and the most prevalent cutaneous and ocular tumor is SCC. Case presentation: We present a case of a 21-year-old male from western Nepal who presented to Tribhuvan University Teaching Hospital with multiple lesions on the face and was diagnosed with SCC and BCC. We comprehensively evaluated the chronology of events and associated pathology, and a detailed review of prior medical and surgical records was performed. Discussion: XP is an uncommon, autosomal recessive disorder with mutations in nucleotide excision repair genes. Patients with XP are more likely to develop cutaneous and ocular neoplasms early in life, which are more aggressive and have a high recurrence rate. Conclusion: Patients with XP can prolong their lives and avoid developing skin cancer by receiving early diagnosis and broad sun protection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.